Risk of Atherosclerosis Due to HMGB1-dependent Platelet-derived Microparticles in Patients with Type 2 Diabetes Mellitus
We measured high mobility group box 1 protein (HMGB1) and platelet-derived microparticles (PDMP) in blood samples from patients with untreated type 2 diabetes mellitus (T2DM). We examined the effects of a combination of sodium/glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DP...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-11-01
|
| Series: | Clinical and Applied Thrombosis/Hemostasis |
| Online Access: | https://doi.org/10.1177/10760296241302082 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850147468932546560 |
|---|---|
| author | Shosaku Nomura MD Takehito Taniura MD Jun Ichikawa MD Ayako Iwama MD Tomoki Ito MD |
| author_facet | Shosaku Nomura MD Takehito Taniura MD Jun Ichikawa MD Ayako Iwama MD Tomoki Ito MD |
| author_sort | Shosaku Nomura MD |
| collection | DOAJ |
| description | We measured high mobility group box 1 protein (HMGB1) and platelet-derived microparticles (PDMP) in blood samples from patients with untreated type 2 diabetes mellitus (T2DM). We examined the effects of a combination of sodium/glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors. Multiple regression analysis of HMGB1 was conducted on data from 252 patients in our previously reported T2DM-related clinical study. The results revealed significant correlations between HMGB1 and PDMP, soluble CD40 ligand, plasminogen activator inhibitor-1, and soluble E-selectin in multivariate analysis. Based on the HMGB1 levels before treatment with combination, 46 T2DM patients in the study were classified into two groups, high and low. The high HMGB1 group showed a significantly lower adiponectin level and higher PDMP production than the low HMGB1 group. T2DM risk significantly and positively correlated with HMGB1 and PDMPs. HMGB1-induced PDMP production was simulated in vitro using healthy platelets. Furthermore, The combination of a SGLT2 inhibitor and a DPP-4 inhibitor significantly reduced HMGB1 and PDMP levels. These results suggest that in addition to abnormal glucose metabolism, HMGB1-dependent PDMP production and the resulting development of atherosclerosis are also a concern in patients with T2DM. |
| format | Article |
| id | doaj-art-007a4de8bfb549c0a702e79a621eab5f |
| institution | OA Journals |
| issn | 1938-2723 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical and Applied Thrombosis/Hemostasis |
| spelling | doaj-art-007a4de8bfb549c0a702e79a621eab5f2025-08-20T02:27:32ZengSAGE PublishingClinical and Applied Thrombosis/Hemostasis1938-27232024-11-013010.1177/10760296241302082Risk of Atherosclerosis Due to HMGB1-dependent Platelet-derived Microparticles in Patients with Type 2 Diabetes MellitusShosaku Nomura MD0Takehito Taniura MD1Jun Ichikawa MD2Ayako Iwama MD3Tomoki Ito MD4 Center of Thrombosis and Hemostasis, , Moriguchi, Japan Department of Internal Medicine, Rokujizo Medical Hospital, Kyoto, Japan First Department of Internal Medicine, , Hirakata, Japan First Department of Internal Medicine, , Hirakata, Japan First Department of Internal Medicine, , Hirakata, JapanWe measured high mobility group box 1 protein (HMGB1) and platelet-derived microparticles (PDMP) in blood samples from patients with untreated type 2 diabetes mellitus (T2DM). We examined the effects of a combination of sodium/glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors. Multiple regression analysis of HMGB1 was conducted on data from 252 patients in our previously reported T2DM-related clinical study. The results revealed significant correlations between HMGB1 and PDMP, soluble CD40 ligand, plasminogen activator inhibitor-1, and soluble E-selectin in multivariate analysis. Based on the HMGB1 levels before treatment with combination, 46 T2DM patients in the study were classified into two groups, high and low. The high HMGB1 group showed a significantly lower adiponectin level and higher PDMP production than the low HMGB1 group. T2DM risk significantly and positively correlated with HMGB1 and PDMPs. HMGB1-induced PDMP production was simulated in vitro using healthy platelets. Furthermore, The combination of a SGLT2 inhibitor and a DPP-4 inhibitor significantly reduced HMGB1 and PDMP levels. These results suggest that in addition to abnormal glucose metabolism, HMGB1-dependent PDMP production and the resulting development of atherosclerosis are also a concern in patients with T2DM.https://doi.org/10.1177/10760296241302082 |
| spellingShingle | Shosaku Nomura MD Takehito Taniura MD Jun Ichikawa MD Ayako Iwama MD Tomoki Ito MD Risk of Atherosclerosis Due to HMGB1-dependent Platelet-derived Microparticles in Patients with Type 2 Diabetes Mellitus Clinical and Applied Thrombosis/Hemostasis |
| title | Risk of Atherosclerosis Due to HMGB1-dependent Platelet-derived Microparticles in Patients with Type 2 Diabetes Mellitus |
| title_full | Risk of Atherosclerosis Due to HMGB1-dependent Platelet-derived Microparticles in Patients with Type 2 Diabetes Mellitus |
| title_fullStr | Risk of Atherosclerosis Due to HMGB1-dependent Platelet-derived Microparticles in Patients with Type 2 Diabetes Mellitus |
| title_full_unstemmed | Risk of Atherosclerosis Due to HMGB1-dependent Platelet-derived Microparticles in Patients with Type 2 Diabetes Mellitus |
| title_short | Risk of Atherosclerosis Due to HMGB1-dependent Platelet-derived Microparticles in Patients with Type 2 Diabetes Mellitus |
| title_sort | risk of atherosclerosis due to hmgb1 dependent platelet derived microparticles in patients with type 2 diabetes mellitus |
| url | https://doi.org/10.1177/10760296241302082 |
| work_keys_str_mv | AT shosakunomuramd riskofatherosclerosisduetohmgb1dependentplateletderivedmicroparticlesinpatientswithtype2diabetesmellitus AT takehitotaniuramd riskofatherosclerosisduetohmgb1dependentplateletderivedmicroparticlesinpatientswithtype2diabetesmellitus AT junichikawamd riskofatherosclerosisduetohmgb1dependentplateletderivedmicroparticlesinpatientswithtype2diabetesmellitus AT ayakoiwamamd riskofatherosclerosisduetohmgb1dependentplateletderivedmicroparticlesinpatientswithtype2diabetesmellitus AT tomokiitomd riskofatherosclerosisduetohmgb1dependentplateletderivedmicroparticlesinpatientswithtype2diabetesmellitus |